Michael King

Work

Analyst Michael King works at BENCHMARK and is focused on the Healthcare sector with 85 price targets and ratings documented since 2013 spanning on 18 stocks. Previously, Michael King worked at HCWAINWRIGHT, JMP. Analyst's average stock valuation to be materialised ratio is 46.22% with an average time for price targets to be met of 153.5 days.

Most recent stock forecast was given on XNCR, Xencor, Inc at 31-Jan-2023.

Michael King best performing recommendations are on NTLA (INTELLIA THERAPEUTICS, INC).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS, INC) at 6/28/2021. The price target of $171 was fulfilled within 3 days with a profit of $37.57 (28.16%) receiving and performance score of 93.86.

Average potential price target upside

ALNY LTRN AGIO ANAB CELG COGT EXEL INFI KTRA NTLA REGN AGEN BMEA CMPX VINC XNCR SONN JSPR

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Hold

143

$-86.75 (-37.76%)

145

14 days ago

2/14 (14.29%)

$-35.63 (-24.57%)

30

Buy

253

$23.25 (10.12%)

226

1 months 21 days ago

61/62 (98.39%)

$50.54 (56.72%)

592

Buy

415

$185.25 (80.63%)

3 months 4 days ago

1/4 (25%)

$110.64 (62.49%)

664

Buy

236

$6.25 (2.72%)

216

3 months 9 days ago

19/19 (100%)

$27.96 (34.44%)

266

Buy

270

$40.25 (17.52%)

273

3 months 9 days ago

5/7 (71.43%)

$23.24 (12.54%)

44

Show more analysts
ALNY LTRN AGIO ANAB CELG COGT EXEL INFI KTRA NTLA REGN AGEN BMEA CMPX VINC XNCR SONN JSPR